FDA Compliance and Quality: What "Homologous Use" Means for Wharton's Jelly

For patients and providers seeking supportive tissue products, regulatory compliance is the cornerstone of safety and quality. Wharton's Jelly–derived products are regulated by the FDA as Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under Section 361 of the Public Health Service Act and 21 CFR Part 1271.

For a product to be regulated solely under Section 361, it must meet several strict criteria. Two of the most important are Minimal Manipulation and Homologous Use.

1. Homologous Use: Matching Function

According to 21 CFR 1271.3(c), homologous use means the HCT/P is used to perform the same basic function or functions in the recipient as in the donor.

In the Donor (Umbilical Cord): Wharton's Jelly functions in vivo to provide cushioning, structural support, and protection to surrounding tissues.

In the Recipient: When used appropriately under Section 361, Wharton's Jelly–derived allografts may only be intended for homologous use in applications where similar cushioning and protective functions are performed. Any other use may be considered a non-homologous use and would require regulation as a drug, device, or biologic under Section 351, which involves a premarket review process.

2. Minimal Manipulation: Preserving Integrity

For cells or non-structural tissues, minimal manipulation means processing that does not alter the relevant biological characteristics of the cells or tissues.

Processing Standards: Reputable tissue banks (like New Life Medical Services) process all tissues in controlled laboratory environments that adhere to current good tissue practices (cGTPs). Products are often processed without the use of gamma irradiation and maintain sterility through validated aseptic techniques, preserving the integrity of the tissue's original structural and biochemical characteristics.

Non-Expansion Practices: Importantly, processing must not include cell expansion or culture manipulation beyond native quantities. Cell expansion can alter biological characteristics and may contribute to cellular senescence, meaning products are preserved in their natural state to maintain alignment with Section 361 requirements.

Ethical Sourcing and Screening

To ensure safety, compliant tissue banks source products from donated birth tissue collected from healthy, consenting mothers at the time of full-term delivery. This process includes a comprehensive medical-social history review and infectious-disease testing (e.g., HIV, Hepatitis B & C) performed by a certified CLIA laboratory to meet FDA standards prior to release for clinical use.

Important Regulatory Disclaimer

The information in this article is for educational purposes only and does not constitute medical advice. Individual results vary. Regenerative therapies at Renew Life Medical, including Wharton's Jelly–derived products, are used strictly for homologous use in accordance with FDA regulatory requirements under Section 361 of the Public Health Service Act and 21 CFR Part 1271. We make no claims regarding the treatment, cure, or prevention of any specific disease or condition.